Genmab — September 2025
-
SOHO 25 abstracts https://clml-25-01.elsevierdigitaledition.com/
-
Tak Darvin for dit mod til at skrive hvad du tænker/tænkte. Det støttede mig i troen på, at Genmab igen var på rette vej. Undre mig over at der ellers har været total tavshed fra andre. Tænker vi alle har brændt fingrene godt og grundigt de sidste par år, og måbende har set på tilbagefaldet. Ingen har turdet at spå. MEN det gør jeg nu, og er enig med dig. Genmab er på vej mod en retfærdig kurs, som er langt over dagens kurs.
-
Genmab Announces Updated Results from Phase 2 EPCORE
NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) https://proinvestor.com/investornyt/1357653/genmab-announces-updated-results-from-phase-2-epcore-nhl-6-study-evaluating-epcoritamab-monotherapy-in-the-outpatient-setting-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl -
Samlet responsrate (ORR): 64,3% af patienterne opnåede respons.
Fuld responsrate (CR): 47,6% opnåede fuld respons, hvilket indikerer betydelig tumorreduktion. -
Medianalderen var 69 år, og 82,6% havde fremskreden sygdom (Ann Arbor stadium III-IV). Her har lymfomet spredt sig til flere lymfeknuder eller til f.eks. knoglemarv, lever, lunger.
-
Genmab har lovende resultater med kræftmiddel som ambulant behandling https://proinvestor.com/investornyt/1357666/genmab-har-lovende-resultater-med-kraeftmiddel-som-ambulant-behandling
-
Investeringspodcasten 287: Nyheder fra Novo, Ørsteds aktieemission, Bavarian Nordics bud og Genmab. https://proinvestor.com/boards/128217
-
Det var da en “OK dag”, for at sige det på nordjysk. Nu er det da noget ved at være aktionær igen. Jeg tror nu vi skal meget langt frem i tid og kurs, før vi ser tilbagefald, som i givet fald vil være midlertidige, i det mindste lang tid frem. Alle analytikere får travlt fremover med at flytte deres target. Incl f.eks UBS, Rothschild m.fl. det er bare om at være med på vognen nu, tror jeg.
-
"Genmab and AbbVie could potentially expand the market for Epkinly (epcoritamab-bysp), their CD20xCD3-directed bispecific antibody for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), with Phase II data showing the feasibility of outpatient use in the DLBCL setting. That could give it a competitive edge against other bispecifics in the same class and even CAR-T cell therapies, which have also been moving to the outpatient setting."
-
did we know this -14-2-25 Centessa granted to Genmab an exclusive worldwide license to leverage the Company’s proprietary LockBody platform to research products against up to three undisclosed targets during a multi-year research period, with an option to take up to three exclusive commercial licenses for worldwide development and commercialization of products against each selected target. https://investors.centessa.com/node/10006/html
-
Genmab will be conducting all research and development activities under the License Agreement and the products may combine Centessa’s LockBody technology with Genmab’s proprietary antibody technologies. The LockBody technology platform is designed to improve the therapeutic index of therapies by allowing targeted conditional activation of potent cell killing mechanisms in diseased tissue only.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind